IDO1 and neoplasm: IDO1 inhibitors combined with radiotherapy, chemotherapy, or immunotherapy can delay tumor progression by reducing the generation of kynurenine and increasing the cytotoxicity of T cells in murine models of CRC (Jia et al., 2018; Jung et al., 2019; Liu et al., 2019).